Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice

Fig. 2

Baseline characteristics and treatment regimens of patients with lung cancer. A The distribution of patients based on different carboplatin treatment regimens (i.e., AUC-2, AUC-5, and AUC-6) at the beginning of the treatment protocol. B Distribution of lung cancer types among different AUC groups. C The number of patients who completed each carboplatin cycle. Boxes with indicate AUC-2 patients, others are for AUC-5/6 patients. D The baseline patient characteristics, including sex, age at diagnosis, weight, and serum creatinine (SrCr) levels across 6 cycles of carboplatin treatment. The top table includes data from all patients, the middle table from AUC-5 and AUC-6 patients (i.e., AUC5/6), and the bottom table from AUC-2 patients (i.e., AUC-2). Values are presented as mean ± standard deviation

Back to article page